By Bryan Koenig ( August 15, 2019, 8:54 PM EDT) -- Buyers of the hypertension medication Exforge will have to pursue their pay-for-delay allegations against the drug's brand maker Novartis and generics company Par Pharmaceutical under a harder-to-prove legal standard, thanks to the U.S. Supreme Court's Actavis decision, a New York federal judge held Thursday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.